Table 2.
Univariate and Multivariate Analysis of YAP1/FAPα, and Clinical Characteristics for Recurrence-Free Survival of NPC Patients
| YAP1 | Univariate analysis | Multivariate analysis | ||
| n = 106 | HR (95% CI) | p value | HR (95% CI) | p value |
| YAP1 Score (≥80 vs. < 80) | 2.255 (0.899–5.653) | 0.083 | 3.841 (1.356–10.883) | 0.011 |
| Treatment Daysa | 1.099 (0.996–1.212) | 0.06 | 1.203 (1.073–1.349) | 0.002 |
| BEDa | 0.943 (0.805–1.103) | 0.46 | 0.884 (0.743–1.052) | 0.164 |
| Age Group (≥48 vs. < 48) | 0.641 (0.262–1.568) | 0.329 | 0.433 (0.133–1.416) | 0.166 |
| Gender (Male vs. Female) | 1.642 (0.549–4.912) | 0.375 | 1.631 (0.409–6.501) | 0.488 |
| T-Stage (T3/4 vs. T1/2) | 2.043 (0.815–5.123) | 0.128 | 5.354 (1.416–20.249) | 0.013 |
| N-Stage (N2/3 vs. N0/1) | 1.541 (0.638–3.719) | 0.336 | 1.388 (0.484–3.979) | 0.541 |
| Chemotherapy (Yes vs. No) | 0.649 (0.249–1.690) | 0.376 | 0.620 (0.208–1.849) | 0.391 |
| Comorbidity (Yes vs. No) | 0.905 (0.361–2.269) | 0.832 | 1.825 (0.579–5.752) | 0.304 |
| Smoking (Yes vs. No) | 1.384 (0.566–3.386) | 0.477 | 1.242 (0.384–4.020) | 0.717 |
| Betel quid (Yes vs. No) | 2.361 (0.941–5.925) | 0.067 | 0.769 (0.201–2.940) | 0.702 |
| Alcohol (Yes vs. No) | 3.478 (1.386–8.727) | 0.008 | 4.211 (1.217–14.574) | 0.023 |
| FAPα | Univariate analysis | Multivariate analysis | ||
| n = 143 | HR (95% CI) | p value | HR (95% CI) | p value |
| FAPα Score (≥80 vs. < 80) | 1.259 (0.528–2.946) | 0.595 | 1.415 (0.519–3.857) | 0.497 |
| Treatment Daysa | 1.124 (1.046–1.209) | 0.002 | 1.170 (1.063–1.288) | 0.001 |
| BEDa | 1.046 (0.958–1.143) | 0.313 | 1.060 (0.967–1.162) | 0.216 |
| Age Group (≥48 vs. < 48) | 0.888 (0.385–2.049) | 0.781 | 0.806 (0.293–2.219) | 0.677 |
| Gender (Male vs. Female) | 1.311 (0.484–3.555) | 0.594 | 0.749 (0.237–2.373) | 0.624 |
| T-Stage (T3/4 vs. T1/2) | 2.209 (0.900–5.420) | 0.084 | 2.339 (0.798–6.854) | 0.121 |
| N-Stage (N2/3 vs. N0/1) | 2.428 (0.990–5.955) | 0.053 | 2.176 (0.823–5.753) | 0.117 |
| Chemotherapy (Yes vs. No) | 0.648 (0.253–1.656) | 0.365 | 0.496 (0.164–1.500) | 0.214 |
| Comorbidity (Yes vs. No) | 1.273 (0.519–3.123) | 0.598 | 1.570 (0.569–4.332) | 0.383 |
| Smoking (Yes vs. No) | 1.777 (0.725–4.359) | 0.209 | 1.015 (0.330–3.125) | 0.979 |
| Betel quid (Yes vs. No) | 2.135 (0.895–5.092) | 0.087 | 0.947 (0.318–2.824) | 0.922 |
| Alcohol (Yes vs. No) | 3.664 (1.565–8.577) | 0.003 | 6.015 (1.839–19.669) | 0.003 |
acontinuous variable. BED Biologically effective dose, HR Hazard ratio, CI Confidence interval